Choose Your Language
Home  /  Introduction to NIPT by GenePlanet

Introduction to NIPT by GenePlanet

The NIPT by GenePlanet is a highly accurate non-invasive prenatal test that screens for chromosomal aneuploidies, including trisomies 21, 18 and 13, from as early as week 10 of pregnancy. NIPT by GenePlanet provides a significantly stronger risk indication than traditional screening procedures. With a sensitivity rate of >99% (validated on over 112,000 pregnancies) and a false positive rate of just 0.05% for trisomies 21, 18 and 13, our test ensures that the number of women undergoing unnecessary invasive diagnostic procedures is significantly reduced.

To date, over 3,500,000 NIPT samples with our technology have been processed worldwide.

NIPT by GenePlanet Test Options

TrisomiesSex Chromosome AneuploidiesDeletion/Duplication SyndromesGender Identification
Down Syndrome (21)Turner SyndromeCri-du-chat Syndrome Male/Female
Edwards Syndrome (18)Klinefelter Syndrome1p36
Patau Syndrome (13)XXX2q33.1
22XYY Prader-Willi/Angelman Syndrome (15q11.2)
16Jacobsen Syndrome (11q23)
9DiGeorge Syndrome II (10p14-p13)
Van der Woude Syndrome (1q32.2)

Testing services for trisomy conditions 21, 18 and 13 are available for twin pregnancies, egg donor pregnancies and IVF pregnancies.

NIPT by GenePlanet Advantage

Most validated NIPT technology on the market with a published study based on the pregnancy outcomes of over 112,000 women.

Proven low redraw rate of just 2.8% based on over 600,000 tests.

Largest capacity and coverage making NIPT by GenePlanet competitive against all other NIPT providers.

A Comparison of Detection Rates*


*NIPT by GenePlanet detection rate for trisomy 21, 18 and 13.

A Comparison of False Positive Rates (FPR)*


**NIPT by GenePlanet FP rate for trisomy 21, 18 and 13

1) Dan S. et al, ‘Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors.’ Prenat. Diagn., 32: 1225–1232. doi: 10.1002/pd.4002
2) Double Blinded Validation Study on 3,464 NIPT Blood Samples.
3) LAU T. K. et al, ‘Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center.’ Ultrasound Obstet Gynecol 2014; 43: 254–264
View all of our published reports relating to NIPT testing.

* Test accuracy figures quoted for NIPT by GenePlanet are based on findings from three separately conducted independent studies (listed above) of non-invasive prenatal testing for fetal chromosomal abnormalities by whole-genome sequencing of maternal plasma DNA. Please refer to the Clinical Data page for more information.